• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Savara Inc. (Amendment)

    2/14/24 4:15:14 PM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SVRA alert in real time by email
    SC 13G/A 1 ea193605-13ga1zambon_savara.htm AMENDMENT NO. 1 TO SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

     

    Savara Inc.

    (Name of Issuer)

     

    Common stock, par value $0.001 per share

     

    (Title of Class of Securities)

     

    805111101

    (CUSIP Number)

     

    January 24, 2024

    (Date of Event which Requires Filing of this Statement)

     

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐Rule 13d-1(b)

     

    ☒Rule 13d-1(c)

     

    ☐Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    1

    Names of Reporting Persons.

    I.R.S. Identification Nos. of above persons (entities only)

     

    Zambon SpA (“ZSPA”)

    2

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)  ☐        (b)  ☒

     

    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization.

     

    Italy

    Number of

    Shares

    Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

    5

    Sole Voting Power

     

    4,680,000 shares

    6

    Shared Voting Power

     

    0 shares

    7

    Sole Dispositive Power

     

    4,680,000 shares

    8

    Shared Dispositive Power

     

    0 shares

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    4,680,000 shares

    10

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

    ☐

    11

    Percent of Class Represented by Amount in Row (9)*

     

    3.46%

    12

    Type of Reporting Person (See Instructions)

     

    CO

     

    2

     

     

    1

    Names of Reporting Persons.

    I.R.S. Identification Nos. of above persons (entities only)

     

    Zambon Company SpA (“ZCSPA”)

    2

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)  ☐        (b)  ☒

     

    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization.

     

    Italy

    Number of

    Shares

    Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

    5

    Sole Voting Power

     

    4,680,000 shares (1)

    6

    Shared Voting Power

     

    0 shares

    7

    Sole Dispositive Power

     

    4,680,000 shares (1)

    8

    Shared Dispositive Power

     

    0 shares

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    4,680,000 shares (1)

    10

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

    ☐

    11

    Percent of Class Represented by Amount in Row (9)*

     

    3.46%

    12

    Type of Reporting Person (See Instructions)

     

    CO

     

    (1)Represents shares held directly by ZSPA, a wholly-owned subsidiary of ZCSPA

     

    3

     

     

    Item 1.

     

    (a)Name of Issuer

     

    Savara Inc.

     

    (b)Address of Issuer’s Principal Executive Offices

     

    1717 Langhorne Newtown Road, Suite 300

    Langhorne, Pennsylvania 19047

     

    Item 2.  

     

    (a)Name of Person Filing

     

    This statement is filed by the following entities and individuals (collectively, referred to as the “Reporting Persons”):

     

    Zambon Company SpA (“ZCSPA”) and Zambon SpA (“ZSPA”). The foregoing entities are collectively referred to as the “Reporting Persons.”

     

    (b)Address of Principal Business Office or, if none, Residence

     

    The address of the principal business office for each of the Reporting Persons is:

    Zambon Company SpA

    Via Lillo del Duca, 10

    Bresso, MI 20091

    Italy

     

    Zambon SpA

    Via Lillo del Duca, 10

    Bresso, MI 20091

    Italy

     

    (c)Citizenship

     

    ZCSPA is a corporation organized under the laws of Italy. ZSPA is a corporation organized under the laws of Italy.

     

    (d)Title of Class of Securities

     

    Common stock, par value $0.001 per share

     

    (e)CUSIP Number

     

    805111101

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable.

     

    Item 4. Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    (a)Amount Beneficially Owned

     

    See Row 9 of cover page for each Reporting Person.

     

    (b)Percent of Class

     

    See Row 11 of cover page for each Reporting Person.

     

    The percentage set forth in this Schedule 13G/A is calculated based upon 135,341,024 shares of Common Stock outstanding as of November 9, 2023, as reported in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023 filed with the Securities and Exchange Commission on November 9, 2023.

     

    4

     

     

    (c)Number of shares as to which such person has:

     

    (i)sole power to vote or to direct the vote

     

    See Row 5 of cover page for each Reporting Person.

     

    (ii)shared power to vote or to direct the vote

     

    See Row 6 of cover page for each Reporting Person.

     

    (iii)sole power to dispose or to direct the disposition of

     

    See Row 7 of cover page for each Reporting Person.

     

    (iv)shared power to dispose or to direct the disposition of

     

    See Row 8 of cover page for each Reporting Person.

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.

     

    Item 6. Ownership of More than Five Percent on Behalf of another Person

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10. Certification

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    5

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    February 13, 2024

     

    ZAMBON COMPANY SPA

     

    By: /s/ Giovanni Magnaghi  
    Name:  Giovanni Magnaghi  
    Title: Authorized Signatory  

     

    ZAMBON SPA
       
    By: /s/ Giovanni Magnaghi  
    Name:  Giovanni Magnaghi  
    Title: Authorized Signatory  

     

     

    6

     

    Get the next $SVRA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SVRA

    DatePrice TargetRatingAnalyst
    5/29/2025$2.00Buy → Neutral
    H.C. Wainwright
    12/20/2024$8.00Overweight
    Wells Fargo
    11/13/2024$7.00 → $5.00Outperform → In-line
    Evercore ISI
    2/15/2024$8.00Mkt Outperform
    JMP Securities
    11/7/2023$7.00Buy
    Guggenheim
    5/16/2023$2.00 → $4.00Hold → Buy
    Jefferies
    3/31/2023$2.00Buy → Hold
    Jefferies
    More analyst ratings

    $SVRA
    Financials

    Live finance-specific insights

    See more
    • Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

      Statistically Significant Improvement in Percent Predicted Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO) Versus Placebo at Week 24 (Primary Endpoint) and Week 48 (Secondary Endpoint) Statistically Significant Improvement in St. George's Respiratory Questionnaire (SGRQ) Total Score at Week 24 (Secondary Endpoint) 97% of Patients Completed Double-Blind Treatment Through Week 48 with No Trial Drug Related Adverse Events Leading to Discontinuation 100% of Patients Completing the 48-Week Double-Blind Period Elected to Participate in the 96-Week Open-Label Period Company Plans to Complete BLA Submission in 1H 2025 Company to Host Webcast Conference Call Today, Ju

      6/26/24 6:30:00 AM ET
      $SVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

      Conference Call to Take Place Tomorrow, Wednesday, June 26, 2024, at 8:00am ET Savara Inc. (NASDAQ:SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it will host a conference call and webcast tomorrow, Wednesday, June 26, 2024, at 8:00am ET to discuss top line results from the pivotal, Phase 3 IMPALA-2 clinical trial assessing the efficacy and safety of molgramostim, an inhaled form of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with aPAP. The Company plans to issue a press release sharing the top line results at approximately 6:30am ET tomorrow, prior to the start of the c

      6/25/24 8:05:00 PM ET
      $SVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SVRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Savara Inc.

      SC 13G - Savara Inc (0001160308) (Subject)

      11/27/24 11:01:58 AM ET
      $SVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Savara Inc.

      SC 13G/A - Savara Inc (0001160308) (Subject)

      11/14/24 5:48:34 PM ET
      $SVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Savara Inc.

      SC 13G/A - Savara Inc (0001160308) (Subject)

      11/12/24 10:25:33 AM ET
      $SVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SVRA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mccracken Joseph S bought $20,825 worth of shares (10,000 units at $2.08), increasing direct ownership by 4% to 260,837 units (SEC Form 4)

      4 - Savara Inc (0001160308) (Issuer)

      6/2/25 7:59:29 AM ET
      $SVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ramsay David A bought $416,250 worth of shares (150,000 units at $2.77), increasing direct ownership by 6% to 2,513,642 units (SEC Form 4)

      4 - Savara Inc (0001160308) (Issuer)

      4/1/25 7:00:04 AM ET
      $SVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Mccracken Joseph S bought $59,072 worth of shares (20,000 units at $2.95), increasing direct ownership by 10% to 210,837 units (SEC Form 4)

      4 - Savara Inc (0001160308) (Issuer)

      11/20/24 7:55:46 AM ET
      $SVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SVRA
    SEC Filings

    See more
    • SEC Form 8-K filed by Savara Inc.

      8-K - Savara Inc (0001160308) (Filer)

      6/6/25 4:48:34 PM ET
      $SVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Savara Inc.

      8-K - Savara Inc (0001160308) (Filer)

      5/27/25 8:13:24 AM ET
      $SVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Savara Inc.

      10-Q - Savara Inc (0001160308) (Filer)

      5/13/25 4:03:22 PM ET
      $SVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SVRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mccracken Joseph S bought $20,825 worth of shares (10,000 units at $2.08), increasing direct ownership by 4% to 260,837 units (SEC Form 4)

      4 - Savara Inc (0001160308) (Issuer)

      6/2/25 7:59:29 AM ET
      $SVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ramsay David A bought $416,250 worth of shares (150,000 units at $2.77), increasing direct ownership by 6% to 2,513,642 units (SEC Form 4)

      4 - Savara Inc (0001160308) (Issuer)

      4/1/25 7:00:04 AM ET
      $SVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Mccabe Kathleen R. claimed ownership of 558,582 shares (SEC Form 3)

      3 - Savara Inc (0001160308) (Issuer)

      3/21/25 4:59:10 PM ET
      $SVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SVRA
    Leadership Updates

    Live Leadership Updates

    See more

    $SVRA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Savara Appoints Braden Parker as Chief Commercial Officer, Effective Immediately

      Mr. Parker has More Than 25 Years of Commercial Leadership Experience and has Launched Multiple Rare Disease Products Savara Inc. (NASDAQ:SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the appointment of Braden Parker as Chief Commercial Officer, effective immediately. Mr. Parker is a seasoned global commercial leader with more than 25 years of experience in the healthcare and biotech industry. Throughout his career, he has developed and executed global commercial plans, including market expansion activities, built high-performance teams, and launched multiple successful rare disease products. Mr. Parker is responsible

      9/24/24 8:05:00 AM ET
      $SVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Savara Reports Third Quarter 2022 Financial Results and Provides Business Update

       Pivotal Phase 3 IMPALA-2 Trial Remains On-Track, Top Line Data Expected End of 2Q 2024 IMPALA-2 is evaluating molgramostim nebulizer solution (molgramostim), a novel inhaled biologic, for the treatment of autoimmune Pulmonary Alveolar Proteinosis (aPAP), a rare lung disease Received Acceptance from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) on a Revised Pediatric Investigation Plan (PIP) for Molgramostim in aPAP Appoints Raymond Pratt, M.D., Chief Medical Officer Company Ends Quarter with ~$134M, Believes it is Sufficiently Capitalized Through 2025 Savara Inc. (NASDAQ:SVRA), a clinical stage biopharmaceutical company focused on rare respiratory disease

      11/10/22 4:05:00 PM ET
      $SVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Savara Announces Resignation of Chief Medical Officer

      Savara Inc. (NASDAQ:SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Badrul Chowdhury, M.D., Ph.D., has resigned from his role as Chief Medical Officer, effective September 9, 2022. "We appreciate Dr. Chowdhury's contributions during his tenure with the company," said Matt Pauls, Chair and CEO, Savara. "His leadership helped progress our molgramostim nebulizer solution (molgramostim) development program through some important milestones and we wish him well in the future." "I am pleased to have been part of the Savara team and wish the company success in the continued development of molgramostim for the treatment of the rare lung

      8/26/22 8:05:00 AM ET
      $SVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Savara Receives Refusal to File (RTF) Letter From the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) for MOLBREEVI* to Treat Patients With Autoimmune Pulmonary Alveolar Proteinosis (autoimmune PAP)

      Savara Inc. (NASDAQ:SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced that the Company received an RTF letter from the FDA for the BLA of MOLBREEVI as a therapy to treat patients with autoimmune PAP. Upon preliminary review, the FDA determined that the BLA submitted in March 2025 was not sufficiently complete to permit substantive review and requested additional data related to Chemistry, Manufacturing, and Controls (CMC). The RTF was not the result of safety concerns, and the FDA did not request or recommend additional efficacy studies. Within the next 30 days, the Company intends to request a Type A meeting with the Age

      5/27/25 8:05:00 AM ET
      $SVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Savara Announces New Employment Inducement Grant

      Savara Inc. (NASDAQ:SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to five new employees. On May 21, 2025, the Compensation Committee of Savara's Board of Directors granted the inducement awards to five new employees who recently joined the Company. The inducement awards consist of options to purchase an aggregate of 85,000 shares of the Company's common stock and restricted stock units (RSUs) covering an aggregate of 75,000 shares of the Company's common stock. These equity awards were granted under the Savara Inc. 2021 Inducement Equity Incentive Plan pursuant to Rule 5635(c)(4) of the NASDAQ Listing

      5/23/25 4:05:00 PM ET
      $SVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Savara Announces Participation in Jefferies Global Healthcare Conference

      Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced members of the management team will host 1x1 meetings and present at the Jefferies Global Healthcare Conference on June 4, 2025, at 9:20am ET/6:20am PT. The live webcast and subsequent replay will be available on the "Events & Presentations" section of the Company's corporate website and will be archived for 90 days. About Savara Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, MOLBREEVI*, is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development

      5/22/25 9:05:00 AM ET
      $SVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SVRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Savara downgraded by H.C. Wainwright with a new price target

      H.C. Wainwright downgraded Savara from Buy to Neutral and set a new price target of $2.00

      5/29/25 8:15:44 AM ET
      $SVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo initiated coverage on Savara with a new price target

      Wells Fargo initiated coverage of Savara with a rating of Overweight and set a new price target of $8.00

      12/20/24 7:52:08 AM ET
      $SVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Savara downgraded by Evercore ISI with a new price target

      Evercore ISI downgraded Savara from Outperform to In-line and set a new price target of $5.00 from $7.00 previously

      11/13/24 8:25:47 AM ET
      $SVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care